nach oben

Magnetic Resonance Materials in Physics, Biology and Medicine

Erschienen in:

01.02.2013 | Review Article

PET/MRI in cancer patients: first experiences and vision from Copenhagen

verfasst von: Andreas Kjær, Annika Loft, Ian Law, Anne Kiil Berthelsen, Lise Borgwardt, Johan Löfgren, Camilla Bardram Johnbeck, Adam Espe Hansen, Sune Keller, Søren Holm, Liselotte Højgaard

Erschienen in: Magnetic Resonance Materials in Physics, Biology and Medicine | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Combined PET/MRI systems are now commercially available and are expected to change the medical imaging field by providing combined anato-metabolic image information. We believe this will be of particular relevance in imaging of cancer patients. At the Department of Clinical Physiology, Nuclear Medicine & PET at Rigshospitalet in Copenhagen we installed an integrated PET/MRI in December 2011. Here, we describe our first clinical PET/MR cases and discuss some of the areas within oncology where we envision promising future application of integrated PET/MR imaging in clinical routine. Cases described include brain tumors, pediatric oncology as well as lung, abdominal and pelvic cancer. In general the cases show that PET/MRI performs well in all these types of cancer when compared to PET/CT. However, future large-scale clinical studies are needed to establish when to use PET/MRI. We envision that PET/MRI in oncology will prove to become a valuable addition to PET/CT in diagnosing, tailoring and monitoring cancer therapy in selected patient populations.

Kjaer A (2006) Molecular imaging of cancer using PET and SPECT. Adv Exp Med Biol 587:277–284PubMedCrossRef

Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2(9):683–693PubMedCrossRef

Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150SPubMedCrossRef

Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R (2000) A combined PET/CT scanner for clinical oncology. J Nucl Med 41(8):1369–1379PubMed

Townsend DW, Beyer T (2002) A combined PET/CT scanner: the path to true image fusion. Br J Radiol 75 Spec No:S24–S30PubMed

Delbeke D, Schoder H, Martin WH, Wahl RL (2009) Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. Sem Nucl Med 39(5):308–340CrossRef

Thoeny HC, Ross BD (2010) Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 32(1):2–16PubMedCrossRef

Padhani AR, Koh DM, Collins DJ (2011) Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 261(3):700–718PubMedCrossRef

Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, Hammoud DA, Rustin GJ, Taouli B, Choyke PL (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11(2):102–125PubMed

10.

Delso G, Furst S, Jakoby B, Ladebeck R, Ganter C, Nekolla SG, Schwaiger M, Ziegler SI (2011) Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med 52(12):1914–1922PubMedCrossRef

11.

Kalemis A, Delattre BM, Heinzer S (2012) Sequential whole-body PET/MR scanner: concept, clinical use, and optimisation after two years in the clinic. The manufacturer’s perspective. Magn Reson Mater Phy. doi:10.1007/s10334-012-0330-y

12.

Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G (2012) Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med 53(6):928–938PubMedCrossRef

13.

Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D’Amore F, Boesen AM, Berthelsen AK, Specht L (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107(1):52–59PubMedCrossRef

14.

Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW, Zilles K, Coenen HH, Langen KJ (2005) O-(2-[18F]fluoroethyl)-l-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128(Pt 3):678–687PubMedCrossRef

15.

Popperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, Gildehaus FJ, Kretzschmar HA, Tonn JC, Tatsch K (2007) FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 34(12):1933–1942PubMedCrossRef

16.

Law M, Young RJ, Babb JS, Peccerelli N, Chheang S, Gruber ML, Miller DC, Golfinos JG, Zagzag D, Johnson G (2008) Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247(2):490–498PubMedCrossRef

17.

Feigl GC, Safavi-Abbasi S, Gharabaghi A, Gonzalez-Felipe V, El Shawarby A, Freund HJ, Samii M (2008) Real-time 3T fMRI data of brain tumour patients for intra-operative localization of primary motor areas. Eur J Surg Oncol 34(6):708–715PubMedCrossRef

18.

Rachinger W, Goetz C, Popperl G, Gildehaus FJ, Kreth FW, Holtmannspotter M, Herms J, Koch W, Tatsch K, Tonn J-C (2005) Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57(3):505–511PubMedCrossRef

19.

Yaman E, Buyukberber S, Benekli M, Oner Y, Coskun U, Akmansu M, Ozturk B, Kaya AO, Uncu D, Yildiz R (2010) Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. Clin Neurol Neurosurg 112(8):662–667PubMedCrossRef

20.

Ganslandt O, Stadlbauer A, Fahlbusch R, Kamada K, Buslei R, Blumcke I, Moser E, Nimsky C (2005) Proton magnetic resonance spectroscopic imaging integrated into image-guided surgery: correlation to standard magnetic resonance imaging and tumor cell density. Neurosurgery 56(2 Suppl):291–298PubMedCrossRef

21.

Stadlbauer A, Ganslandt O, Buslei R, Hammen T, Gruber S, Moser E, Buchfelder M, Salomonowitz E, Nimsky C (2006) Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. Radiology 240(3):803–810PubMedCrossRef

22.

Stadlbauer A, Gruber S, Nimsky C, Fahlbusch R, Hammen T, Buslei R, Tomandl B, Moser E, Ganslandt O (2006) Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology 238(3):958–969PubMedCrossRef

23.

Stadlbauer A, Nimsky C, Buslei R, Salomonowitz E, Hammen T, Buchfelder M, Moser E, Ernst-Stecken A, Ganslandt O (2007) Diffusion tensor imaging and optimized fiber tracking in glioma patients: histopathologic evaluation of tumor-invaded white matter structures. NeuroImage 34(3):949–956PubMedCrossRef

24.

Gruner JM, Paamand R, Kosteljanetz M, Broholm H, Hojgaard L, Law I (2012) Brain perfusion CT compared with (15)O-H (2)O PET in patients with primary brain tumours. Eur J Nucl Med Mol Imaging 39(11):1691–1701PubMedCrossRef

25.

Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, Cumming P, Bartenstein P, Tonn JC, Kreth FW, la Fougere C (2012) MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 39(6):1021–1029PubMedCrossRef

26.

Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, Muigg A, Virgolini IJ, Staffen W, Trinka E, Gotwald T, Jacobs AH, Stockhammer G (2011) O-(2–18F-fluoroethyl)-l-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med 52(6):856–864PubMedCrossRef

27.

Grosu AL, Weber WA, Franz M, Stark S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63(2):511–519PubMedCrossRef

28.

Thorwarth D, Muller AC, Pfannenberg C, Beyer T (2012) Combined PET/MR Imaging using (68)Ga-DOTATOC for radiotherapy treatment planning in meningioma patients. Recent Result Cancer Res 194:425–439CrossRef

29.

Kumar R, Shandal V, Shamim SA, Halanaik D, Malhotra A (2010) Clinical applications of PET and PET/CT in pediatric malignancies. Expert Rev Anticancer Ther 10(5):755–768PubMedCrossRef

30.

Purz S, Mauz-Korholz C, Korholz D, Hasenclever D, Krausse A, Sorge I, Ruschke K, Stiefel M, Amthauer H, Schober O, Kranert WT, Weber WA, Haberkorn U, Hundsdorfer P, Ehlert K, Becker M, Rossler J, Kulozik AE, Sabri O, Kluge R (2011) [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin’s lymphoma. J Clin Oncol 29(26):3523–3528PubMedCrossRef

31.

Kluge R, Korholz D (2011) [Role of FDG-PET in staging and therapy of children with Hodgkin lymphoma]. Die Bedeutung des FDG-PET fur die Stadieneinteilung und Therapie des Hodgkin-Lymphoms im Kindesalter. Klin Padiatr 223(6):315–319PubMedCrossRef

32.

Fahey FH, Treves ST, Adelstein SJ (2011) Minimizing and communicating radiation risk in pediatric nuclear medicine. J Nucl Med 52(8):1240–1251PubMed

33.

Lassmann M, Biassoni L, Monsieurs M, Franzius C, Dosimetry E, Paediatrics C (2008) The new EANM paediatric dosage card: additional notes with respect to F-18. Eur J Nucl Med Mol Imaging 35(9):1666–1668PubMedCrossRef

34.

Lassmann M, Biassoni L, Monsieurs M, Franzius C, Jacobs F, Dosimetry E, Paediatrics C (2007) The new EANM paediatric dosage card. Eur J Nucl Med Mol Imaging 34(5):796–798PubMedCrossRef

35.

Kaste SC (2011) Imaging pediatric bone sarcomas. Radiol Clin North Am 49(4):749–765, vi–vii

36.

Krohmer S, Sorge I, Krausse A, Kluge R, Bierbach U, Marwede D, Kahn T, Hirsch W (2010) Whole-body MRI for primary evaluation of malignant disease in children. Eur J Radiol 74(1):256–261PubMedCrossRef

37.

Biederer J, Hintze C, Fabel M (2008) MRI of pulmonary nodules: technique and diagnostic value. Cancer Imaging 8:125–130PubMedCrossRef

38.

Kwee TC, Takahara T, Vermoolen MA, Bierings MB, Mali WP, Nievelstein RA (2010) Whole-body diffusion-weighted imaging for staging malignant lymphoma in children. Pediatr Radiol 40(10):1592–1602, quiz 1720–1591

39.

Lin C, Itti E, Luciani A, Haioun C, Meignan M, Rahmouni A (2010) Whole-body diffusion-weighted imaging in lymphoma. Cancer imaging 10 Spec no A:S172–S178PubMedCrossRef

40.

Willowson KP, Bailey EA, Bailey DL (2012) A retrospective evaluation of radiation dose associated with low dose FDG protocols in whole-body PET/CT. Australas Phys Eng Sci Med 35(1):49–53PubMedCrossRef

41.

Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, Pfannenberg C, Pichler BJ, Reimold M, Stegger L (2010) Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med 51(8):1198–1205PubMedCrossRef

42.

Schwenzer NF, Schmidt H, Claussen CD (2012) Whole-body MR/PET: applications in abdominal imaging. Abdom Imaging 37(1):20–28PubMedCrossRef

43.

Drzezga A, Souvatzoglou M, Eiber M, Beer AJ, Furst S, Martinez-Moller A, Nekolla SG, Ziegler S, Ganter C, Rummeny EJ, Schwaiger M (2012) First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 53(6):845–855PubMedCrossRef

44.

Antoch G, Bockisch A (2009) Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging 36(Suppl 1):S113–S120PubMedCrossRef

45.

Chang Q, Wu N, Ouyang H, Huang Y (2012) Diffusion-weighted magnetic resonance imaging of lung cancer at 3.0 T: a preliminary study on monitoring diffusion changes during chemoradiation therapy. Clin Imaging 36(2):98–103PubMedCrossRef

46.

Sharma U, Baek HM, Su MY, Jagannathan NR (2011) In vivo 1H MRS in the assessment of the therapeutic response of breast cancer patients. NMR Biomed 24(6):700–711PubMed

47.

Denholt CL, Binderup T, Stockhausen MT, Poulsen HS, Spang-Thomsen M, Hansen PR, Gillings N, Kjaer A (2011) Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer. Nucl Med Biol 38(4):509–515PubMedCrossRef

48.

Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, Binderup T, Rasmussen P, Elema D, Klausen TL, Holm S, von Benzon E, Hojgaard L, Kjaer A (2012) Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med 53(8):1207–1215PubMedCrossRef

49.

Jensen MM, Erichsen KD, Bjorkling F, Madsen J, Jensen PB, Hojgaard L, Sehested M, Kjaer A (2010) Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PLoS One 5(9):e12965PubMedCrossRef

50.

Dunet V, Rossier C, Buck A, Stupp R, Prior JO (2012) Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med 53(2):207–214PubMedCrossRef

51.

Hansen AE, Kristensen AT, Law I, McEvoy FJ, Kjaer A, Engelholm SA (2012) Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT. Radiother Oncol 102(3):424–428PubMedCrossRef

52.

Oxboel J, Schoedt-Eskesen C, El-Ali H, Madsen J, Kjaer A (2012) 64Cu-NODAGA-c(RGDyK) is a promising new angiogenesis PET tracer: correlation between tumor uptake and integrin-aVß3 expression in human neuroendocrine tumor xenografts. Int J Mol Imaging 2012:379807PubMed

53.

Persson M, Madsen J, Ostergaard S, Jensen MM, Jorgensen JT, Juhl K, Lehmann C, Ploug M, Kjaer A (2012) Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. J Nucl Med 53(1):138–145PubMedCrossRef

54.

Persson M, Madsen J, Ostergaard S, Ploug M, Kjaer A (2012) 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. Nucl Med Biol 39(4):560–569PubMedCrossRef

55.

Sattler B, Jochimsen T, Barthel H, Sommerfeld K, Stumpp P, Hoffmann KT, Gutberlet M, Villringer A, Kahn T, Sabri O (2012) Physical and organizational provision for installation, regulatory requirements and implementation of a simultaneous hybrid PET/MR-imaging system in an integrated research and clinical setting. Magn Reson Mater Phy. doi:10.1007/s10334-012-0347-2

56.

Keller SH, Holm S, Hansen AE, Sattler B, Andersen F, Klausen TL, Hojgaard L, Kjaer A, Beyer T (2012) Image artifacts from MR-based attenuation correction in clinical, whole-body PET/MRI. Magn Reson Mater Phy. doi:10.1007/s10334-012-0345-4

57.

Wagenknecht G, Kaiser HJ, Mottagny FM, Herzog H (2012) MRI for attenuation correction in PET: methods and challenges. Magn Reson Mater Phy. doi:10.1007/s10334-012-0353-4

Titel: PET/MRI in cancer patients: first experiences and vision from Copenhagen
verfasst von: Andreas Kjær
Annika Loft
Ian Law
Anne Kiil Berthelsen
Lise Borgwardt
Johan Löfgren
Camilla Bardram Johnbeck
Adam Espe Hansen
Sune Keller
Søren Holm
Liselotte Højgaard
Publikationsdatum: 01.02.2013
Verlag: Springer-Verlag
Erschienen in: Magnetic Resonance Materials in Physics, Biology and Medicine / Ausgabe 1/2013
Print ISSN: 0968-5243
Elektronische ISSN: 1352-8661
DOI: https://doi.org/10.1007/s10334-012-0357-0

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

PET/MRI in cancer patients: first experiences and vision from Copenhagen

Abstract

Neu im Fachgebiet Radiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update Radiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Evaluation of an attenuation correction method for PET/MR imaging of the head based on substitute CT images

Approaches for the optimization of MR protocols in clinical hybrid PET/MRI studies

PET–MR imaging using a tri-modality PET/CT–MR system with a dedicated shuttle in clinical routine

Radiotracers for positron emission tomography imaging

Physical and organizational provision for installation, regulatory requirements and implementation of a simultaneous hybrid PET/MR-imaging system in an integrated research and clinical setting

Sequential whole-body PET/MR scanner: concept, clinical use, and optimisation after two years in the clinic. The manufacturer’s perspective

Neu im Fachgebiet Radiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update Radiologie